文献速递真菌感染艾滋病与性传播感染

乌干达实施基于单次高剂量脂质体两性霉素B的诱导治疗HIV相关隐球菌脑膜炎:一项比较性前瞻性队列研究

Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在乌干达成年HIV相关隐球菌脑膜炎患者中开展观察性队列,179例接受AMBITION-cm方案(单次10 mg/kg脂质体两性霉素B联合14天氟胞嘧啶和氟康唑)常规治疗,与AMBITION-cm试验干预组171例比较。10周生存率分别为68.6%(95%CI 61.6%-76.3%)和71.7%(95%CI 65.2%-78.8%),绝对风险差-3.1%(95%CI -13.1%至6.9%,P=.61);早期杀真菌活性无差异(0.42 vs 0.39 log10CFU/mL/天,P=.80)。

要点

  • 常规诊疗中实施AMBITION-cm方案,10周生存率与临床试验干预组无显著差异。
  • 早期杀真菌活性两组无差异(0.42 vs 0.39 log10CFU/mL/天,P=.80)。
  • 出院存活且可随访者中,因持续颅内压升高再住院发生率为2.8%(4/144)。

核心结论

  • 在常规诊疗中实施AMBITION-cm方案治疗隐球菌脑膜炎,结局与AMBITION-cm临床试验观察到的结果相似;住院期间颅内压管理和出院后意识是优化结局的关键组成部分。

研究设计与样本

  • 观察性队列研究,2022-2023年纳入乌干达成年隐球菌脑膜炎患者179例,接受AMBITION-cm方案(单次10 mg/kg脂质体两性霉素B联合14天氟胞嘧啶和氟康唑)并在常规诊疗中行治疗性腰椎穿刺。
  • 对照为2018至2021年在同一地点随机分配至AMBITION-cm试验干预组的171例乌干达成人。
  • 比较10周生存率和脑脊液早期杀真菌活性。

主要发现

  • 观察队列10周生存率为68.6%(95%CI 61.6%-76.3%),AMBITION-cm试验干预组为71.7%(95%CI 65.2%-78.8%),绝对风险差-3.1%(95%CI -13.1%至6.9%,P=.61),无显著差异。
  • 早期杀真菌活性两组无差异(0.42 vs 0.39 log10CFU/mL/天,P=.80)。
  • 观察队列中初始出院存活且有随访数据的参与者,因持续颅内压升高再住院发生率为2.8%(4/144)。

关键数值与推荐

  • 2022年世界卫生组织(WHO)推荐单次10 mg/kg脂质体两性霉素B联合14天氟胞嘧啶和氟康唑(AMBITION-cm方案)用于HIV相关隐球菌脑膜炎的诱导治疗,基于多中心AMBITION-cm试验结果。

临床怎么用

  • 作者认为,住院期间颅内压管理和出院后意识是优化结局的关键组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2022, the World Health Organization (WHO) recommended a single 10 mg/kg dose of liposomal amphotericin B in combination with 14 days of flucytosine and fluconazole (AMBITION-cm regimen) for induction therapy of human immunodeficiency virus (HIV)-associated cryptococcal meningitis, based on the results of the multisite AMBITION-cm trial. We evaluated outcomes after real-world implementation of this novel regimen in Uganda. METHODS: We enrolled Ugandan adults with cryptococcal meningitis into an observational cohort receiving the AMBITION-cm regimen with therapeutic lumbar punctures in routine care during 2022-2023. We compared 10-week survival and CSF early fungicidal activity with the outcomes observed in the AMBITION-cm clinical trial conducted at the same sites. RESULTS: During 2022-2023, 179 adults were treated with the AMBITION-cm regimen via routine care and compared to the 171 adults randomized to the AMBITION-cm trial interventional arm in Uganda from 2018 to 2021. No significant difference in 10-week survival occurred between the observational cohort (68.6%; 95% confidence interval [CI]: 61.6%-76.3%) and AMBITION-cm trial participants in the intervention arm (71.7%; 95% CI: 65.2%-78.8%; absolute risk difference = -3.1%; 95% CI: -13.1% to 6.9%; P = .61). Early fungicidal activity did not differ (0.42 vs 0.39 log10CFU/mL/day; P = .80) between groups. Among observational cohort participants discharged alive initially and for whom follow-up data were available, the incidence of re-hospitalizations due to persistently elevated intracranial pressure was 2.8% (4/144). CONCLUSIONS: The AMBITION-cm regimen for cryptococcal meningitis resulted in similar outcomes as observed in the AMBITION-cm clinical trial when implemented in routine care. Intracranial pressure management during hospitalization and awareness after discharge are key components of optimizing outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gakuru J, Kagimu E, Dai B, et al. Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study. Clin Infect Dis. 2025. PMID: 39180324. doi:10.1093/cid/ciae413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。